Vivanza Biosciences Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 15.2 million compared to INR 40.8 million a year ago. Revenue was INR 15.42 million compared to INR 41.21 million a year ago. Net loss was INR 0.476 million compared to net income of INR 1.66 million a year ago. Basic loss per share from continuing operations was INR 0.12 compared to basic earnings per share from continuing operations of INR 0.41 a year ago. Diluted loss per share from continuing operations was INR 0.12 compared to diluted earnings per share from continuing operations of INR 0.41 a year ago.
For the nine months, sales was INR 45.55 million compared to INR 34.95 million a year ago. Revenue was INR 50.89 million compared to INR 38.14 million a year ago. Net income was INR 5.33 million compared to INR 0.9 million a year ago. Basic earnings per share from continuing operations was INR 1.33 compared to INR 0.23 a year ago. Diluted earnings per share from continuing operations was INR 1.33 compared to INR 0.23 a year ago.